UBS Asset Management Americas Inc. Acquires 18,690 Shares of Bruker Corporation (BRKR)
UBS Asset Management Americas Inc. grew its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 25.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 91,748 shares of the medical research company’s stock after purchasing an additional 18,690 shares during the quarter. UBS Asset Management Americas Inc. owned approximately 0.06% of Bruker Corporation worth $2,646,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in BRKR. BlackRock Inc. boosted its stake in Bruker Corporation by 26,266.0% during the 1st quarter. BlackRock Inc. now owns 4,607,722 shares of the medical research company’s stock worth $107,498,000 after purchasing an additional 4,590,246 shares during the last quarter. AJO LP acquired a new position in shares of Bruker Corporation during the 2nd quarter valued at about $46,075,000. FMR LLC boosted its position in shares of Bruker Corporation by 26.4% during the 1st quarter. FMR LLC now owns 7,146,000 shares of the medical research company’s stock valued at $166,716,000 after acquiring an additional 1,491,140 shares during the last quarter. Point72 Asset Management L.P. boosted its position in shares of Bruker Corporation by 2,261.9% during the 1st quarter. Point72 Asset Management L.P. now owns 1,152,600 shares of the medical research company’s stock valued at $26,890,000 after acquiring an additional 1,103,800 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Bruker Corporation by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 9,832,452 shares of the medical research company’s stock valued at $229,391,000 after acquiring an additional 277,111 shares during the last quarter. 65.42% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/14/ubs-asset-management-americas-inc-acquires-18690-shares-of-bruker-corporation-brkr.html.
In related news, VP Mark Munch sold 21,061 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total transaction of $631,198.17. Following the sale, the vice president now directly owns 60,524 shares in the company, valued at approximately $1,813,904.28. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Frank H. Laukien bought 2,335 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $27.39 per share, for a total transaction of $63,955.65. Following the completion of the acquisition, the chief executive officer now owns 37,791,386 shares in the company, valued at approximately $1,035,106,062.54. The disclosure for this purchase can be found here. Company insiders own 35.20% of the company’s stock.
Several research analysts have recently weighed in on BRKR shares. BidaskClub raised shares of Bruker Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th. Wells Fargo & Company cut shares of Bruker Corporation from a “market perform” rating to an “underperform” rating in a research report on Wednesday, July 12th. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and set a $24.00 price target on shares of Bruker Corporation in a research report on Tuesday, September 26th. Zacks Investment Research raised shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research report on Thursday, July 6th. Finally, Barclays PLC reissued an “equal weight” rating and set a $30.00 price target (up previously from $26.00) on shares of Bruker Corporation in a research report on Monday, July 17th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $26.70.
Shares of Bruker Corporation (NASDAQ BRKR) opened at 30.89 on Friday. Bruker Corporation has a one year low of $19.58 and a one year high of $30.97. The company has a 50-day moving average of $29.68 and a 200 day moving average of $27.37. The stock has a market capitalization of $4.90 billion, a price-to-earnings ratio of 30.80 and a beta of 1.09.
Bruker Corporation (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.03. The company had revenue of $414.90 million for the quarter, compared to the consensus estimate of $384.75 million. Bruker Corporation had a return on equity of 26.66% and a net margin of 9.65%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the business posted $0.20 EPS. Equities research analysts forecast that Bruker Corporation will post $1.12 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 22nd. Stockholders of record on Tuesday, September 5th were issued a $0.04 dividend. The ex-dividend date was Thursday, August 31st. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.52%. Bruker Corporation’s dividend payout ratio (DPR) is 16.00%.
Bruker Corporation Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR).
Receive News & Stock Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related stocks with our FREE daily email newsletter.